Posted by Michael Wonder on 31 Oct 2025
ICER publishes final evidence report on treatment for non-cystic fibrosis bronchiectasis
30 October 2025 - Independent appraisal committee voted unanimously on the positive net health benefit of brensocatib; but current pricing represents “low” value for money.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of brensocatib (Brinsupri, Insmed) for the treatment of non-cystic fibrosis bronchiectasis.
